anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
TScan Therapeutics · pitchdeck

TScan Therapeutics | IPO Presentation Deck | 43 slides

43 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

TScan Therapeutics | IPO Presentation Deck | 43 slides

TScan Therapeutics · 2021-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 30 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits
— 0/3 slides
33.3% 1/3 slides 66.7% 2/3 slides 100% 3/3 slides 100% 3/3 slides Solution 14 slides 100% 14/14 slides 100% 14/14 slides · 44 hits
— 0/14 slides
42.9% 6/14 slides 71.4% 10/14 slides 100% 14/14 slides 100% 14/14 slides Traction 12 slides 100% 12/12 slides 100% 12/12 slides · 49 hits
— 0/12 slides
25% 3/12 slides 25% 3/12 slides · 4 hits 100% 12/12 slides
— 0/12 slides
Team 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

43
every slide · same image gating as the playbook
01
Slide 1
Features company logo and date.front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detail
04
The slide uses a stylized 'T' graphic with a timeline-like bullet structure.summarize
Open slide detail
05
The slide uses a grid layout to present 12 team members with headshots, names, titles, and logos of past/associated organizations.other
Open slide detailBeat · Team
06
The slide uses a process flow to explain the 'Learning' phase of their technology platform.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
07
The slide title is likely a continuation from a previous slide (e.g., '...to treat patients who are not eligible for standard therapies').present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
08
Uses a before-after-bridge style logic to illustrate the clinical advantage of multiplexing.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
09
The slide uses a Gantt-style visualization to show the current development stage of multiple drug candidates.plan_implementation
Open slide detailBeat · SolutionLoop · Golden Circle
10
The slide uses a color-coded legend to distinguish between liquid and solid tumor programs.plan_implementation
Open slide detailBeat · SolutionLoop · Golden Circle
11
transition
Open slide detailBeat · SolutionLoop · Golden Circle
12
Uses a before-after-bridge framework to contrast current therapy limitations with TScan's solution.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
13
The slide uses a process flow diagram to explain a proprietary biotechnology platform.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
14
The slide uses a Venn diagram to explain the scope of their target discovery platform.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
15
The chart demonstrates the specificity of the TargetScan platform by highlighting MAGE-A3 as the primary target with significantly higher fold-enrichment.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
16
The chart displays fold-enrichment vs protein fragment number, identifying specific gene targets.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
17
The slide illustrates a dual-platform approach to TCR discovery and validation.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
18
The slide uses a flow-chart style diagram to position TScan's technology as an evolution of current standard-of-care cell therapies.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
19
transition
Open slide detailBeat · SolutionLoop · Golden Circle
20
Uses a Who/Why/When framework to define the market opportunity.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
21
The chart shows a clear upward trend in HCT procedures from 2000 to 2018, segmented by indication (AML, MDS, ALL).size_opportunity
Open slide detailBeat · ProblemLoop · Cost Of Inaction
22
Uses a process flow diagram to show the patient journey and the specific point of failure (relapse).frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
23
The slide uses a circular process flow to show the interaction between the patient's condition and the donor-derived TCR therapy.present_solution
Open slide detail
24
The slide shows three distinct charts: a time-course line graph, a bar chart for survival at 90 hours, and a bar chart comparing cell viability across differentpresent_solution
Open slide detailBeat · Traction
25
The slide uses microscopy imagery to demonstrate therapeutic efficacy.present_solution
Open slide detailBeat · Traction
26
The chart shows a scatter plot where the vast majority of data points are at zero, indicating no off-target binding.present_solution
Open slide detailBeat · Traction
27
The slide uses a process flow to explain patient stratification for a clinical trial.present_solution
Open slide detailBeat · Traction
28
transition
Open slide detailBeat · Traction
29
Uses a Venn diagram to show overlap in Head & Neck cancers, and a central 'ImmunoBank' repository feeding into multiplexed TCR-T arms.present_solution
Open slide detailBeat · Traction
30
The slide highlights target expression overlap to justify multiplexed therapy.size_opportunity
Open slide detailBeat · Traction
31
The chart shows fold-enrichment of protein fragments, highlighting a 'Novel Head & Neck Target' alongside positive controls.show_traction
Open slide detailBeat · Traction
32
The chart shows fold-enrichment of protein fragments, highlighting three specific targets identified from patient data.present_solution
Open slide detailBeat · Traction
33
The chart uses a log scale on the y-axis to compare expression levels across multiple tissue types.present_solution
Open slide detailBeat · Traction
34
Slide 34 from TScan Therapeutics deck.show_traction
Open slide detailBeat · Traction
35
The slide uses a process flow to demonstrate the company's R&D pipeline progress.show_traction
Open slide detailBeat · Traction
36
The slide uses a process flow to explain the mechanism of action for the company's platform.present_solution
Open slide detail
37
transition
Open slide detail
38
The slide uses a diagram to illustrate the mechanism of the T-Integrate system (transposon/transposase integration into T cell DNA).present_solution
Open slide detail
39
plan_implementation
Open slide detail
40
Uses a honeycomb/hexagonal diagram to represent the three focus areas.present_solution
Open slide detail
41
The slide highlights a specific partnership deal structure.other
Open slide detail
42
The slide uses a hexagonal diagram to represent disease areas (Oncology, Infectious Disease, Autoimmune Disease).show_traction
Open slide detail
43
summarize
Open slide detail